February 2019

Clinical trial on neridronate in Germany

Aachen. CRPS/Sudeck's disease was conducted by the pharmaceutical manufacturer Grünenthal, Aachen, to conduct a clinical study on the active ingredient neridronate. Neridronic acid) launched an aminobisphosphate. In various clinics in Germany, sufferers can take part in this clinical trial.

The studies will be conducted at sites in the US, Canada, Germany, France, the UK, Spain, Ukraine, the Czech Republic, Slovakia, Poland, Serbia, Australia, New Zealand and South Korea.

There are two placebo-controlled clinical trials that currently conduct and recruit patients. One also has clinical study centers in Germany where patients can be included in the study if they are eligible according to all inclusion/exclusion criteria.

Here's the link clinical trials.gov for this study: https://clinicaltrials.gov/ct2/show/NCT03530345?term=neridronic+acid&cond=CRPS&rank=1

The clinical study centers in Germany are:

  • Center for Clinical Research Dr. med. Medical. I. Schoel, Bad Homburg, tel: 06172/1710784
  • Clinical Research Berlin Mitte GmbH, Berlin, Tel: 030/206580-800
  • BAG anesthesia, pain therapy, palliative care, cottbus, tel: 03552/890785
  • Clinical Research Hamburg GmbH, Hamburg; Phone: 040/460763030
  • Clinical Research Hannover Mitte, Hanover, Tel: 0511/169765-0
  • Department and Department of Neurology University Medicine Mainz, Mainz, Tel: 0613iconfin0-2222
  • Clinical Research Schwerin GmbH, Schwerin, Tel: 0385/557740

Patients will need to contact the sites and potentially make an appointment to check suitability. Please note that an important criterion is that the CRPS duration from the onset of signs and symptoms is no more than 2 years. People with a longer CRPS duration cannot be considered.

Recruitment should continue until early 2020.

For inclusion in the clinical trial, there are various admission requirements named in the following document. There is also more information on the study. Contact can be made about this.

Position paper on the treatment of CRPS in Europe/Standards

A position paper on the treatment of CRPS in Europe was published in the European Journal of Pain in January. Well-known medical practitioners from Great Britain, Germany, Switzerland, Belgium, the Netherlands, France, Denmark and Poland as well as from Irsael and Australia have together put together the current methods and best practices to raise standards for treatment Set. So far, there are different good and bad treatment routes in each country and the secured diagnosis "CRPS" is either not made or not made in time.

So far, we have only been present in English for the position paper, but we are working on a translation that we will publish here.

The CRPS network has translated the position paper into German for a better understanding. The translation can be downloaded here.